Scott Tyler Aaronson MD
Adjunct Professor, Psychiatry, University of Maryland School of Medicine Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System
Join to View Full Profile
6501 N Charles StTowson, MD 21204
Phone+1 410-938-3125
Fax+1 410-938-3111
Dr. Aaronson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Scott Aaronson is a psychiatrist in Towson, MD and is affiliated with Sheppard Pratt Health System. He received his medical degree from Harvard Medical School and has been in practice 36 years. His research covers novel treatments for difficult to treat mood and anxiety disorders and includes multiple studies with psychedelics as well as experimental neuromodulation techniques. He has more than 100 publications and over 3000 citings.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1985
Harvard Medical SchoolClass of 1981
Certifications & Licensure
MD State Medical License 2001 - 2026
MA State Medical License 1982 - 2001
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Treatment-Resistant Depression Registry Start of enrollment: 2006 Jan 01
- Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1) Start of enrollment: 2011 Sep 01
- Investigating tDCS as a Treatment for Unipolar and Bipolar Depression Start of enrollment: 2012 Jun 01
Publications & Presentations
PubMed
- Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), ...Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Robin Carhart-Harris, Jamie Chai-Rees
Journal of Affective Disorders. 2026-01-15 - Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Sara Ellis, Catherine Bostian, Anna Donnelly, Wendy Feng, Katherine Eisen
Journal of Affective Disorders. 2025-11-15 - The trajectory of symptom change over the course of transcranial magnetic stimulation for major depressive disorder.Linda L Carpenter, Scott T Aaronson, Todd Hutton, Kenneth Pages, A John Rush
Brain Stimulation. 2025-10-09
Press Mentions
New Clinical Trial Conducted at Sheppard Pratt Identifies Predictors of Response to Vagus Nerve Stimulation for Treatment-Resistant DepressionOctober 13th, 2025- Why You Should Care Who Controls PsychedelicsMay 7th, 2021
- Correction: COMPASS Pathways Establishes Centre of Excellence with Sheppard Pratt to Accelerate Research and Improve Patient Experience in Mental Health CareJanuary 8th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
